Clinical Trial Update: A Study of the Safety and Pharmacokinetics of an Anti-Inflammatory Therapeutic Antibody (MABp1) in Patients With Type 2 Diabetes [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and pharmacokinetics of the anti-inflammatory antibody MABp1 in patients with Type 2 Diabetes has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• MABp1

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Type 2 Diabetes | Phase 2 | Status: COMPLETED